Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117599 | 0.88 | LMNA (0.38) | ALDH1A1TSHRUSP2LMNACYP2C9 | |
| SCHEMBL14355430 | 0.85 | ALDH1A1 (0.54) | ALDH1A1TSHRUSP2HRH3LMNA | |
| SCHEMBL19992499 | 0.84 | KDM4E (0.45) | ALDH1A1HRH3KDM4E | |
| SCHEMBL23517478 | 0.83 | ALDH1A1 (0.49) | ALDH1A1TSHRUSP2HRH3LMNA | |
| SCHEMBL16566607 | 0.83 | ALDH1A1 (0.49) | ALDH1A1TSHRUSP2LMNA | |
| SCHEMBL2116176 | 0.83 | CYP2C9 (0.36) | ALDH1A1LMNACYP2C9KDM4EGPR119 | |
| SCHEMBL2114244 | 0.82 | ALDH1A1 (0.45) | ALDH1A1TSHRUSP2HRH3KDM4E | |
| SCHEMBL15468146 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TSHRUSP2 | |
| SCHEMBL2116626 | 0.81 | LMNA (0.39) | TSHRHRH3LMNACYP2C9GPR119 | |
| SCHEMBL429615 | 0.80 | TSHR (0.40) | TSHRHRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | ALDH1A1 596/4885TSHR 146/4885USP2 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.